Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,985.33
(
0.82%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
95.52
(
0.53%
)
Bitcoin
78,035.33
(
2.24%
)
News Focus
News Focus
Post# of 405181
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

sunspotter

Send PM Follow Ignore
Followers 227
Posts 17336
Boards Moderated 5
Alias Born 06/02/2007

sunspotter

Member Level

Re: Drano post# 117595

Tuesday, 08/11/2015 3:36:20 PM

Tuesday, August 11, 2015 3:36:20 PM

Post# of 405181
"And let's not forget that these great results were from Phase 1 SAFETY trials, they were not even optimized as to dosage size and schedule"

Exactly.

Efficacy was not a primary endpoint, and post hoc cherry picking of data from Phase I studies has led to many Phase II failures among anti-cancer candidates.

Today's PR was a disgrace whether you look at from a GCP or a CSR perspective.

No wonder Mr. Market is selling (at least I assume it's Mr. Market, but maybe insiders know soemthing too).

"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

"Nobody ever went broke underestimating the intelligence of the American public."

H. L. Mencken

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote